Biomedical (applied/exploratory)
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261200800045C
- Awardee
-
Myriad Rbm, Inc. UEI KJ9RNTDFC3D1 Part of Myriad Genetics Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,148,568
Award facts
- Opportunity
-
- PHS20081 Solicitation number
- Contract value 100% obligated
- $1,148,568.17 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 519190 All Other Information Services
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 8 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Austin, TX 78759, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | -$21 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $487,488 | |
| Exercise an Option | $511,226 | |
| Original award | $149,875 |
About this award
This is a $1,148,568.17 firm-fixed-price contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Myriad RBM, Inc., a subsidiary of Myriad Genetics, Inc. The contract was set aside for small businesses and awarded under the Small Business Innovation Research (SBIR) program, Phase I. It is for biomedical (applied/exploratory) research and development, with a period of performance from September 30, 2008, to March 29, 2011.
Based on the award history provided, Myriad Genetics, the parent company of Myriad RBM, has been awarded multiple firm-fixed-price contracts and orders from federal agencies like the Department of Veterans Affairs (VA), Veterans Health Administration (VHA), and Defense Health Agency (DHA) to provide its Prolaris genetic testing services for prostate cancer diagnosis and treatment guidance. These contracts involve performing quantitative PCR analysis on prostate biopsy samples to assess tumor aggressiveness and help guide treatment decisions for prostate cancer patients.
Quick answers
Who was awarded contract HHSN261200800045C?
HHSN261200800045C was awarded to Myriad Rbm, Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2008.
How much is contract HHSN261200800045C worth?
The government has obligated $1,148,568 on HHSN261200800045C.
Was contract HHSN261200800045C competed?
The extent of competition for HHSN261200800045C was full and open competition after exclusion of sources. The government received 8 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award